Mitokinin
Dr. Taylor served as President and CEO of Deciphera Pharmaceuticals from 2014 until retiring in 2019. He remains a Deciphera Director. Prior to joining Deciphera, Dr. Taylor was CEO of Ensemble Therapeutics, a small molecule drug discovery company, from 2007 to 2013. Prior to joining Ensemble, Dr. Taylor was Senior Vice President for Pfizer’s Global R&D division and served as Vice President, Drug Development at Warner-Lambert/Parke-Davis, where he led early and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin®. Dr. Taylor has authored or coauthored 65 manuscripts and published abstracts and is co-inventor on eight patents.
Dr. Taylor holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy, was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania and holds B.S. magna cum laude in Chemistry from the University of South Florida.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.